OnKure Therapeutics, Inc. (OKUR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $108.33M
Last updated: Nov 17, 2026 at 11:05 AM ET
OnKure Therapeutics, Inc. (OKUR) Competitors
The companies most similar to OnKure Therapeutics are NeOnc Technologies Holdings, Inc. Common Stock (NTHI), Nkarta (NKTX) and Oncolytics Biotech (ONCY). By market cap, OnKure Therapeutics ranks 4th of the 13 companies on this page; Keros Therapeutics (KROS) is the largest at $202.13M.
Peer Comparison
OKUR's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| OnKure Therapeutics (OKUR) | $108.33M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | $141.66M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Nkarta Inc (NKTX) | $85.23M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Oncolytics Biotech Inc (ONCY) | $48.51M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Champions Oncology Inc (CSBR) | $65.49M | N/A | 1.0x | -1.9% | N/A | 8.8% | 0.00% |
| OUTLOOK THERAPEUTICS INC (OTLK) | $100.54M | N/A | N/A | 0.0% | -776.9% | -99.4% | 0.00% |
| TuHURA Biosciences Inc (HURA) | $88.58M | N/A | N/A | 0.0% | -81.8% | 0.0% | 0.00% |
| Kazia Therapeutics Ltd ADR (KZIA) | $75.65M | N/A | N/A | 0.0% | N/A | 312.4% | 0.00% |
| Cardiff Oncology Inc (CRDF) | $56.49M | N/A | 115.5x | 0.0% | N/A | -14.1% | 0.00% |
| Pmv Pharmaceuticals Inc (PMVP) | $95.93M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Keros Therapeutics Inc (KROS) | $202.13M | N/A | 4.9x | -151.4% | N/A | 180.5% | 0.00% |
| OKYO Pharma Limited (OKYO) | $70.85M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Zura Bio Limited Class A Ordinary Shares (ZURA) | $119.44M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $86.91M | N/A | 4.9x | 0.0% | -429.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to OnKure Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy... | NTHI competitors |
| Nkarta Inc (NKTX) | Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. | NKTX competitors |
| Oncolytics Biotech Inc (ONCY) | Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer. | ONCY competitors |
| Champions Oncology Inc (CSBR) | Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States. | CSBR competitors |
| OUTLOOK THERAPEUTICS INC (OTLK) | Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic... | OTLK competitors |
| TuHURA Biosciences Inc (HURA) | TuHURA Biosciences Inc is a pioneering biotechnology firm committed to advancing immunotherapy solutions for cancer and autoimmune diseases. | HURA competitors |
| Kazia Therapeutics Ltd ADR (KZIA) | Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia. | |
| Cardiff Oncology Inc (CRDF) | Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. | CRDF competitors |
| Pmv Pharmaceuticals Inc (PMVP) | PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53... | PMVP competitors |
| Keros Therapeutics Inc (KROS) | Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery... | KROS competitors |
| OKYO Pharma Limited (OKYO) | OKYO Pharma Limited, a preclinical biopharmaceutical company, is engaged in developing therapies for patients suffering from inflammatory eye diseases and eye... | |
| Zura Bio Limited Class A Ordinary Shares (ZURA) | Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. | ZURA competitors |
Frequently Asked Questions About OKUR
Who are OnKure Therapeutics' main competitors?
The companies most similar to OnKure Therapeutics include NeOnc Technologies Holdings, Inc. Common Stock (NTHI), Nkarta (NKTX), Oncolytics Biotech (ONCY), Champions Oncology (CSBR) and OUTLOOK THERAPEUTICS INC (OTLK), listed from the closest match.
Who is OnKure Therapeutics' biggest competitor?
Keros Therapeutics (KROS) is the largest of the similar companies at $202.13M; NeOnc Technologies Holdings, Inc. Common Stock (NTHI) is the closest match by business profile, size, sector and industry.
How does OKUR stock compare with its competitors?
OKUR's net margin is 0.0% against a peer median of 0.0%.
Which of OnKure Therapeutics' competitors pays a higher dividend?
OnKure Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is OnKure Therapeutics bigger than its competitors?
No. OnKure Therapeutics is 4th by market cap among the 13 companies on this page; the largest is Keros Therapeutics (KROS) at $202.13M.
OKUR pages: Overview, Earnings, Forecast, Financials, Competitors